Cyr61 mediates oxaliplatin resistance in colorectal cancer cells by regulating Bcl-xL expression

Although the clinical application of oxaliplatin (L-OHP) has improved the survival of colorectal cancer (CRC) patients, approximately half of patients with CRC fail to achieve good clinical outcomes, indicating resistance to L-OHP therapy. Cysteine-rich protein 61 (Cyr61), a multifunctional extracel...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yanfang, Kang, Yanli, Lin, Zhen, Zeng, Menglu, Shi, Pengchong, Lin, Jia, Lu, Pingxia, Luo, Li, Cao, Yingping, Zhu, Xianjin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7974528/
https://www.ncbi.nlm.nih.gov/pubmed/33753993
http://dx.doi.org/10.7150/jca.48891

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7974528/
https://www.ncbi.nlm.nih.gov/pubmed/33753993
http://dx.doi.org/10.7150/jca.48891

Ejemplares similares